Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Predicting tuberculosis relapse based on 28-day CFU, RS ratio, and/or drug contribution for novel regimens in the relapsing mouse model.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Adaptive immunity shapes baseline physiology of M. tuberculosis in high-dose versus low-dose infection BALB/c mouse drug treatment models.
Journal: Antimicrobial agents and chemotherapy
Published: July 31, 2026
Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model.
Journal: Antimicrobial agents and chemotherapy
Published: April 29, 2026
Adaptive immunity shapes baseline physiology of M. tuberculosis in high-dose versus low-dose infection BALB/c mouse drug treatment models.
Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026
A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model.
Journal: Antimicrobial agents and chemotherapy
Published: January 15, 2026
Same class, different activity: Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits Mycobacterium tuberculosis ribosomal rRNA synthesis.
Journal: bioRxiv : the preprint server for biology
Published: January 09, 2026
Mind the gap: Understanding discordance between culture- and a non-culture-based measure of bacterial burden in murine tuberculosis treatment models.
Journal: bioRxiv : the preprint server for biology
Published: December 25, 2025
Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment.
Journal: Frontiers in pharmacology
Published: October 27, 2025
Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo.
Journal: Antimicrobial agents and chemotherapy
Published: September 18, 2025
Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment.
Journal: Frontiers in pharmacology
Published: July 16, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.
Journal: Contemporary clinical trials
Published: June 05, 2025
Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo.
Journal: PLoS pathogens
Published: April 24, 2025
Last Updated: 09/26/2026